Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03146234
Recruitment Status : Completed
First Posted : May 9, 2017
Last Update Posted : August 28, 2019
CARsgen Therapeutics Co., Ltd.
Information provided by (Responsible Party):
RenJi Hospital

Brief Summary:
This study is designed to determine the safety and efficacy of CAR-GPC3 T cells in patients with relapsed or refractory hepatocellular carcinoma. Single or multiple doses of GPC3-targeted CAR T cells will be given to subjects with unmet medical needs for which there are no effective therapies known at this time.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Genetic: CAR-GPC3 T cells Not Applicable

Detailed Description:

A single arm, open-label pilot study is designed to determine the safety, tolerability and engraftment potential of CAR-GPC3 T cells in patients with GPC3-positive hepatocellular carcinoma.

Primary objectives:

Determine the safety, tolerability and cytokinetics of the autologous T cells transduced with the anti- GPC3 lentiviral vector in patients with hepatocellular carcinoma.

Secondary objectives:

Make a preliminary evaluation on the efficacy of CAR-GPC3 T cells in patients with hepatocellular carcinoma by the following parameters:

Objective response rate (ORR); Disease Control Rate (DCR); Time of tumor progression (TTP); Overall survival (OS).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study of Redirected Autologous T Cells With a GPC3-targeted Chimeric Antigen Receptor in Patients With Refractory Hepatocellular Carcinoma
Actual Study Start Date : March 17, 2017
Actual Primary Completion Date : October 18, 2018
Actual Study Completion Date : October 18, 2018

Arm Intervention/treatment
Experimental: CAR-GPC3 T cells

Autologous T Cells with a GPC3-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.

Lymphodepletion conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -6 to Day -3 prior to CAR-GPC3 T cells infusion.

Genetic: CAR-GPC3 T cells

Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.

Classical "3+3" dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study.

Other Name: GPC3 Redirected Autologous Cells

Primary Outcome Measures :
  1. Safety and tolerance [ Time Frame: 24 weeks ]

    Study related adverse events are defined as signs above CTCAE Grade 3, laboratory toxicities and clinical events occurred at any time from the first day of infusion to week 24 that are "possibly", "likely", or "definitely" related to the study, including infusion related toxicity and CAR-GPC3 T cells related toxicity. Include but not limited to:

    Fever; Chills; Nausea, vomiting and other gastrointestinal symptoms; Fatigue; Hypotension; Respiratory distress; Tumor lysis syndrome; Cytokine release syndrome; Neutropenia, thrombocytopenia; Liver and kidney dysfunction; Other toxicities.

Secondary Outcome Measures :
  1. Engraftment [ Time Frame: 2 years ]
    Duration of in vivo survival of CAR-GPC3 T cells is defined as "engraftment". The primary engraftment endpoint is the number of DNA vector copies per mL blood of CAR-GPC3 T cells at regular intervals through week 4 following the initial infusion. Q-PCR for CAR-GPC3 vector sequences will be performed until any 2 sequential tests are negative, documented as engraftment and persistence of CAR-GPC3 T cells.

Other Outcome Measures:
  1. Anti-tumor responses to CAR-GPC3 T cell infusions [ Time Frame: 2 years ]
    Objective response rate (ORR); Progression-free survival (PFS); Time of tumor progression (TTP); Overall survival (OS).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Age of 18-70 years;
  2. Pathologically confirmed advanced hepatocellular carcinoma (HCC);
  3. ≥1 measurable target lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1);
  4. Tumor tissue positive for GPC3 expression per immunohistochemical staining (IHC) assay;
  5. Estimated survival > 12 weeks;
  6. Child-Pugh grade A;
  7. ECOG performance score of 0-1;
  8. HBV-DNA < 200 IU/mL if positive for HBsAg or HBcAb. Patients positive for HBsAg shall receive anti-viral treatment per "The guideline of prevention and treatment for chronic hepatitis B: a 2015 update";
  9. Have adequate venous access for apheresis or venous blood collection;
  10. White blood cells ≥ 2.5 x 109/L, platelet ≥ 60×109/L, haemoglobin ≥ 9.0 g/dL, lymphocyte ≥ 0.4×109/L
  11. Serum albumin ≥ 30 g/dL, serum lipase and amylase≤1.5 upper limit of normal (ULN), serum creatinine ≤ 1.5 ULN and endogenous creatinine clearance ≥ 40mL/min, ALT and AST ≤ 5 ULN, Serum total bilirubin ≤ 2.5 ULN, Prothrombin Time is less than 4s longer than normal;
  12. Negative serum pregnancy test within 14 days before CAR T infusion, and with willingness to use reliable contraceptive methods to avoid pregnancy until 12 months after CAR T infusions for females of childbearing age; Having undergone sterilization procedure or with willingness to use reliable contraceptive methods to avoid pregnancy for males with female partner of childbearing age during the study;
  13. Able to understand and sign the informed consent form

Exclusion criteria:

If the patient meets any of the exclusion criteria, the patient must be excluded from the study.

  1. Pregnant or lactating female patients;
  2. Positive serum tests for HCV, HIV, or syphilis;
  3. Presence of HBV/HCV coinfection;
  4. Presence of any uncontrollable active infection, such as, but not limited to, active tuberculosis
  5. History of systemic administration of steroids (not including inhaled steroids), or other immunosuppressant drugs within 2 weeks before apheresis;
  6. History of allergy to immunotherapy and related drugs, or β-lactam antibiotics, or history of other severe allergy;
  7. History or current presence of hepatic encephalopathy;
  8. Presence of ascites with clinical significance that is defined as positive focused physical examination for ascites, or ascites that requires treatment intervention (not including any ascites shown on image examinations without the need for clinical intervention);
  9. ≥ 50% of normal liver occupied with HCC tumor tissue, or presence of tumor thrombus in the portal vein, or mesenteric vein, or inferior vena based on image analysis;
  10. Presence of HCC metastatic lesion in the central nervous system, or presence of other diseases of central nervous system with clinical significance;
  11. Presence of heart disease that requires treatment intervention, or poorly controlled hypertension (systolic pressure > 160 mmHg, or diastolic pressure > 100 mmHg);
  12. Presence of active auto-immune disease that requires immunosuppressant treatment;
  13. History of organ transplantation or currently on the waiting list for organ transplantation, including, but not limited to, liver transplantation;
  14. Anti-HCC therapies including, but not limited to, surgical resection, interventional therapy, radiation therapy, chemotherapy, and immunotherapy, within 2 weeks before apheresis;
  15. History of receiving anti-PD-1 or anti-PD-L1 monoclonal antibodies, or other immunotherapy;
  16. History of other malignancies in the past 5 years, or presence of other active malignancies (not including cervical cancer in situ and basal cell carcinomas);
  17. Presence of other serious diseases or conditions, including uncontrolled diabetes (HbA1c > 7% with treatment); severe cardiac dysfunction with LVEF < 45%; myocardial infarction, unstable angina, or unstable arrhythmia in the past 6 months pulmonary embolism; chronic obstructive pulmonary disease; interstitial lung disease; forced expiratory volume in 1 second (FEV1) < 60%, gastric ulcer; history of gastrointestinal bleeding, or confirmed tendency for gastrointestinal bleeding;
  18. Determined by the investigator to be lack of compliance for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03146234

Layout table for location information
China, Shanghai
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai, China, 20001
Sponsors and Collaborators
RenJi Hospital
CARsgen Therapeutics Co., Ltd.
Layout table for investigator information
Principal Investigator: Bo Zhai, MD RenJi Hospital
Layout table for additonal information
Responsible Party: RenJi Hospital Identifier: NCT03146234    
Other Study ID Numbers: CG1006
First Posted: May 9, 2017    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases